Home・Список акций・Legend Biotech Corp ADR

Legend Biotech Corp ADR

Закрыт

СекторЗдравоохранение

19.11 1.16

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

18.8

Макс.

19.34

Ключевые показатели
By Trading Economics
Доход	-24M -54M
Продажи	-2.5M 305M
Прибыль на акцию	-0.15
Рентабельность продаж	-17.851
Сотрудники	3,100
EBITDA	-24M -32M

Рекомендации
By TipRanks
Рекомендации	Покупка
Прогноз на 12 месяцев	+175.38% upside

Дивиденды
By Acuity
Следующий отчет о доходах	11 авг. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-1B 3.7B
Предыдущая цена открытия	17.95
Предыдущая цена закрытия	19.11

Новостные настроения

By Acuity

100%

320 / 340 Рейтинг в Healthcare

Legend Biotech Corp ADR График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

3 авг. 2026 г., 22:01 UTC

Shares of Legend Biotech Corp are higher in after-market trading, reflecting gains since Monday's close amid broader market advances in tech and oil-sensitive sectors.

31 июл. 2026 г., 23:56 UTC

Shares of Legend Biotech Corp. are higher in after-market trading, despite a slight decline earlier in the session and broader market weakness.

30 июл. 2026 г., 22:41 UTC

Shares of Legend Biotech Corp are trading lower in after-market hours, continuing a trend of unusual weakness since Thursday's close.

29 июл. 2026 г., 19:27 UTC

Social Media

Legend Biotech Corp shares are lower, extending a four-session decline. Raymond James projects a 12-month price target range of $58 to $86.

28 июл. 2026 г., 22:56 UTC

Shares of Legend Biotech Corp are trading higher in after-market hours, despite no specific news identified. The broader market showed gains earlier in the day.

27 июл. 2026 г., 23:16 UTC

Legend Biotech Corp shares are higher in after-market hours, having briefly reached a session high. The price remains below its 20-day moving average.

24 июл. 2026 г., 19:16 UTC

News

UBS downgraded Legend Biotech Corp to Neutral and cut its price target to $28, contributing to a decline in shares during Friday's session.

22 июл. 2026 г., 18:31 UTC

Legend Biotech Corp shares are lower today amid broader market weakness and rising geopolitical tensions, despite an earlier peak during the session.

21 июл. 2026 г., 16:46 UTC

Legend Biotech Corp. shares are higher today, reaching a session peak amid rising crude oil prices, despite trading below its 20-day moving average.

20 июл. 2026 г., 19:01 UTC

Legend Biotech Corp is trading higher during Monday's session, rebounding from an earlier low and showing strength after a week of declines.

Сравнение c конкурентами

Изменение цены

Legend Biotech Corp ADR Прогноз

Целевая цена

By TipRanks

175.38% рост

Прогноз на 12 месяцев

Средняя 52.35 USD 175.38%

Максимум 80 USD

Минимум 28 USD

Основано на мнении 10 аналитиков Wall Street, спрогнозировавших целевые цены для Legend Biotech Corp ADR на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

10 ratings

Покупка

Удержание

Продажа

Основано на мнении 10 аналитиков, присваивавших рейтинги акциям Legend Biotech Corp ADR – Данные за последние 3 месяца.

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Legend Biotech Corp ADR

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.